Patrick Ajah is not aiming to establish just another pharmaceutical company. He is the Managing Director and CEO of May & Baker Nigeria Plc (MBN), and he is maneuvering one of Nigeria’s oldest healthcare institutions through a very tough era and turning that pressure into a long-term relevance strategy.
He is at the forefront of a market that is full of opportunities but also very challenging. Changes in currency rates, increase in production costs, interruptions in the supply chain, and new laws may quickly change the situation in the Nigerian pharmaceutical industry.
Nevertheless, Ajah is aware of the main thing: The demand for healthcare in Nigeria is increasing so quickly that it cannot be ignored; it is being caused by the growth of the population, the increase in health awareness, and the simultaneous occurrence of infectious and noncommunicable diseases.
For him, the opportunity is clear. Companies that remain innovative, agile, and uncompromising on quality will not only survive, they will lead.
Building a Healthcare Brand That Nigerians Actually Trust
In industries like pharmaceuticals, trust is not a brand asset. It is the business model.
Ajah speaks proudly about May & Baker’s deep connection with Nigerian households, pointing to M & B Paracetamol, a product that has become a trusted name over generations.
But his leadership approach is not to lean on legacy alone. His focus is to scale that same trust into the future by replicating success across newer launches like MULTAMIN-PLUS, Maysedyl, and Diamet SR, strengthening both prescription and consumer health categories.
This balanced portfolio matters. Many healthcare companies swing heavily toward either prescription drugs or consumer wellness. Ajah is positioning MBN as a business that can win in both lanes, because Nigerian healthcare demand is not one-dimensional anymore.
A Legacy Company That Refuses to Stay Stuck in the Past
May & Baker Nigeria Plc has history that very few businesses in the country can match. It was registered in Nigeria on 4 September 1944, making it Nigeria’s first pharmaceutical manufacturing company.
Ajah highlights how the company’s roots trace back to England, founded by chemists in 1834, later evolving through global ownership changes connected to major European players. What is striking is that today, the Nigerian offshoot remains the one that still carries the original name.
But Ajah’s story here is not nostalgia. It is positioning.
He frames May & Baker as a legacy business that constantly evolves to remain relevant in a changing healthcare market, building deep relationships with healthcare professionals, institutions, and everyday consumers.
Distribution Power: The Competitive Advantage Most People Miss
A great product means nothing if it cannot reach the patient.
Ajah understands distribution as a core growth engine, not a backend function. MBN’s extensive distribution network supports the movement of products across Nigeria’s vast geographic spread, backed by key distributors and a strong sales force.
This is where the business strength becomes tangible. In a country as large and complex as Nigeria, logistics determines access. And access is what decides market leadership.
Subsidiaries, Scale, and a Vaccine Vision
Under Ajah’s leadership narrative, May & Baker is not only a single-company story. It is a group strategy.
MBN operates with three subsidiaries:
- Osworth Nigeria
- Tydipacks Nigeria
- Servisure Nigeria
The group also holds a joint venture with the Federal Government of Nigeria: Biovaccines Nigeria, created for the production and distribution of vaccines.
This matters because it signals a bigger ambition: supporting national health priorities, not only selling products. In today’s world, vaccine capability is not just public good. It is national resilience, supply assurance, and strategic capacity.
Local Manufacturing as a National and Commercial Strategy
Ajah’s strongest business message is tied to self-sufficiency.
He acknowledges that Nigeria’s pharmaceutical industry is pushing toward stronger domestic production, and May & Baker sees this moment as a chance to deepen local manufacturing and expand its healthcare portfolio.
One of the standout assets in this mission is PharmaCentre, May & Baker’s WHO-standard pharmaceutical production facility in Ota, Ogun State, commissioned in 2011.
The facility was GMP-certified by WHO in 2014 and is currently undergoing recertification, with specific products being submitted for WHO pre-qualification.
From a business perspective, this is about credibility and competitiveness. A WHO-standard facility strengthens confidence in quality, opens pathways for wider acceptance, and reduces overdependence on imports.
And in a market where affordability and consistent supply can determine public health outcomes, local manufacturing is not only strategic. It is essential.
Expanding into Cardiometabolic Care and Wellness
Ajah is also steering MBN into spaces where Nigeria’s health challenges are growing fastest.
He highlights expansion into cardiometabolic care and wellness, showing how the company is anticipating future demand patterns rather than reacting late.
That move has business logic behind it. The rise of noncommunicable diseases increases the demand for long-term medication, prevention-focused health products, and patient education.
For MBN, it is a growth pathway that also aligns with national healthcare needs.
The Leader Behind the Legacy
Patrick Ajah’s leadership sits at the meeting point of heritage and ambition.
He is protecting what May & Baker already represents: trust, product quality, and national relevance built over decades. But he is also pushing it into a future shaped by local manufacturing, wider therapeutic reach, and stronger healthcare access.
In his words, May & Baker’s strength is its blend of trusted brands, forward-looking innovation, and deep commitment to improving healthcare outcomes in Nigeria.
In a sector that demands both precision and purpose, Ajah is proving that the strongest companies do not only sell medicine.
They build the systems that keep a nation healthier.
